Psilocybin Microdosing on Cognition, Mood and Quality of Life

This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.

Inclusion Criteria: * No history of psychedelic use * Able to read, speak, and understand English * Able and willing to provide written informed consent, and willing to commit to study protocol * Women of childbearing potential must be on a highly effective birth control method Exclusion Criteria: * Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment * Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V * Current or past alcohol or substance use disorder per DSM-V * IQ \30 minutes or concussion in last 30 days * Any medical/neurological condition that could compromise neurocognitive performance (e.g., epilepsy, multiple sclerosis, fetal alcohol syndrome) * Anyone deemed unsafe to study personnel for any reason; e.g., suicidal ideation * Focal brain lesion seen on structural MRI * MRI contraindications (e.g., implanted metallic object, severe claustrophobia)